百濟神州(06160.HK)料2030年前在港引進4隻新藥
百濟神州(06160.HK)香港及台灣總經理陳益雅指,目前集團在港引入的三款創新藥,包括IL-6抑制劇、BTK抑制劑及PD-1抑制劑,其中兩款已獲得政府資助,可於公立醫院使用。集團計劃2030年前於港引入4隻新藥,另料今年下半年在香港會新增兩個新適應症。
集團於今年首季首次錄得盈利,陳益雅指,集團目前的研發費用佔銷售比例很高,全球研發團隊有約1,100人。對比起其他公司會將試驗階段外判,集團會進行自主試驗,有助將研發成本降低30%,研發的時間亦可以縮短35%。集團亦有應用AI於前端篩選候選藥物,以提升效率。
香港及澳門業務副總監鄭永康指,集團旗下3隻已在港註冊的藥物當中,IL-6和BTK的首個適應症已進入政府藥物名冊及安全網,而PD-1剛剛於香港完成註冊,集團會持續與政府溝通,希望可將其盡快納入到安全網。
他又提到,2023年落實的「1+」政策有助加快引入創新藥來港,集團未來推出的新藥都會善用該政策,目標是希望以最快方式於香港完成藥物註冊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.